Pseudomonas aeruginosa-induced infection and degradation of human wound fluid and skin proteins ex vivo are eradicated by a synthetic cationic polymer.
OBJECTIVE
Antimicrobial peptides are important effectors of innate immunity. Bacteria display multiple defence mechanisms against these peptides. For example, Pseudomonas aeruginosa releases potent proteinases that inactivate the human cathelicidin LL-37. Hence, in conditions characterized by persistent bacterial colonization, such as in P. aeruginosa-infected skin wounds, there is a need for efficient means of reducing bacterial load. Here, the effect of the cationic molecule polyhexamethylenebiguanide (PHMB) was evaluated.


METHODS
Infection models in human wound fluid and human skin were established. Radial diffusion methods, bacterial growth and bactericidal assays were used for determination of effects of PHMB on bacteria in the presence of plasma, wound fluid or human skin. At the protein and tissue levels, SDS-PAGE, light microscopy and scanning electron microscopy were used to study the effects of P. aeruginosa infection before and after addition of PHMB.


RESULTS
PHMB killed common ulcer-derived bacteria in the presence of human wound fluid. Furthermore, elastase-expressing P. aeruginosa completely degraded wound fluid proteins as well as human skin during infection ex vivo. The infection, and consequent protein degradation, was reversed by PHMB.


CONCLUSIONS
The ex vivo infection models presented here should be helpful in the screening of novel antimicrobials and constitute a prerequisite for future clinical studies.
Werthén
M
M
Mölnlycke Health Care AB, SE-40252 Göteborg, Sweden.
Davoudi
M
M
Sonesson
A
A
Nitsche
D P
DP
Mörgelin
M
M
Blom
K
K
Schmidtchen
A
A
D023181:Antimicrobial Cationic Peptides / Q000494:pharmacology*; D001645:Biguanides / Q000494:pharmacology*; D015169:Colony Count, Microbial; D005122:Exudates and Transudates / Q000378:metabolism / Q000382:microbiology; D006801:Humans; D008954:Models, Biological; D011506:Proteins / Q000378:metabolism*; D011552:Pseudomonas Infections / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000254:growth & development; D012867:Skin / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology / Q000473:pathology; D014946:Wound Infection / Q000382:microbiology*
D023181:Antimicrobial Cationic Peptides; D001645:Biguanides; D011506:Proteins; C031233:polihexanide